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Anne B Modeste-Duval1, Jean P. Lacour8, Marie H. L’Anthoe¨n-Arditi9, Christian Thuillez10 and
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It has been suggested that chronic eczematous eruptions of the elderly could be associated with chronic drug
exposure. To determine the drugs associated with these eruptions, we conducted a case–control study on 102
cases and 204 controls. Cases were consecutive patients older than 60 years presenting with an eczematous
eruption that had evolved continuously or recurrently for more than 3 months without a reliable cause. Two
controls were matched to each case on age, sex, in/outpatient origin, and center. Information about drug
exposure was obtained from patients and their pharmacists. Drug use for more than 3 months within the year
preceding the eruption was compared between cases and controls. An association was found between calcium
channel blockers (CCB) and eczema, with a matched OR (odds ratio) of 2.5 (95% CI (confidence interval):
1.3–4.6). To ascertain the course of patients after CCB withdrawal, two ancillary studies were performed on 74
patients with eczematous eruptions from our department before the case–control study period, and on 101
patients registered in the French ‘‘Pharmacovigilance’’ database. Healing of these eruptions after CCB
withdrawal occurred in 83 and 68% of these cases, respectively. The long-term use of CCB is a risk factor for
chronic eczematous eruptions of the elderly.
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INTRODUCTION
Eczematous eruptions are quite common in the elderly
(Kligman, 1979; Beauregard and Gilchrest, 1987; Thivolet
and Nicolas, 1990). Some cases correspond to contact
dermatitis or atopic dermatitis, whereas other cases corres-
pond to atypical forms of various dermatoses such as bullous
pemphigoid, mycosis fungoides, or scabies (Honig et al.,
1991; Scolo et al., 1995). Additionally, some cases cannot
be related to a reliable cause. We recently reported
findings from a retrospective series of 83 elderly patients
referred to our Department of Dermatology for chronic or
recurrent extensive eczematous eruptions (Morin et al.,
2002). At least a reliable cause could be identified in 48
patients (58%), namely extensive contact dermatitis in 19
patients (23%), eczema-like mycosis fungoides in 10 patients
(12%), atopic dermatitis in seven patients (8%), eczema-like
bullous pemphigoid in six patients (7%), and scabies in six
patients (7%). For the remaining 35 patients (42%), no cause
could be determined. Comparison of clinical and histological
features of patients with or without an identified cause
showed a more frequent localization of skin lesions on sun-
exposed areas (P¼0.004), and a higher frequency of sparse
keratinocyte necrosis on biopsy specimens (P¼0.007) among
patients without an identified cause. Moreover, patients
without an identified cause had a higher frequency of chronic
(i.e., X3 months) drug intake (P¼0.02). These findings
suggested that some of these eruptions of unknown cause
could be caused by chronic drug intake. The most frequently
recorded drugs were diuretics, calcium channel blockers
(CCB), angiotensin-converting enzyme inhibitors, nitrates,
and benzodiazepines. We conducted a multicenter case–-
control study to ascertain the risks of chronic eczematous
eruptions in relation with chronic drug intake in the elderly.
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RESULTS
Cases and controls
During the study period, 255 cases were assessed for
eligibility. One hundred and forty-one patients were ex-
cluded because a reliable cause of their eczematous eruption
was identified, namely contact dermatitis (n¼62), eczema-
like mycosis fungoides (n¼ 26), atopic dermatitis (n¼ 21),
scabies (n¼18), or eczema-like bullous pemphigoid (n¼ 14).
Additionally, 12 patients were excluded because the in-
formation on their drug intake could not be elicited or
verified from their pharmacist. Of the remaining 102 cases
(66 males and 36 females), there were 49 inpatients and 53
outpatients. Their mean age was 76.677.6 years. Preferential
localization of skin lesion on sun-exposed areas was noted in
17 cases (17%). However, no clear-cut seasonality in the
onset of these eruptions was evidenced. All but two cases
(98%) complained of pruritus. The mean delay since initial
onset of skin lesions was 12.574.5 months.
Two hundred and four patients were selected as controls
from a series of 245 patients of whom 21 refused to
participate in the study, and 20 could not have their drug
intake elicited or verified. Seventy-six control patients (37%)
presented with the following common dermatological con-
ditions: actinic keratosis, basal cell carcinoma, seborrheic
keratosis, nevi, seborrheic dermatitis, or cutaneous xerosis.
The remaining 128 control patients (63%) presented with
acute non-dermatological conditions including pneumonia,
hip fracture, peritonitis, and various other acute medical or
surgical conditions.
Comparison of drug intakes between cases and controls
Controls appeared well matched to cases for age, sex, in/
outpatient status, and center (Table 1). Ninety-two cases
(90%) and 186 controls (91%) had taken at least one drug for
a period of at least 3 months during the year preceding the
onset of the eruption in cases and the corresponding period in
controls. Mean number of drugs chronically taken was
4.773.3 per patient in cases and 4.573.2 in controls
(Table 1). Among cases, the main drugs used were diuretics
(37%), converting enzyme inhibitors (28%), CCB (26%),
hypolipidemic drugs (25%), and salicylates (22%) (Table 2).
Comparison of the prevalence of chronic drug intake
between cases and controls showed a significant association
between the occurrence of eczematous eruptions and
chronic intake of CCB. Twenty-six cases (26%) and 25
controls (12%) reported chronic intake of CCB, respectively,
corresponding to a matched odds ratio (OR) of 2.29 (95%
confidence interval (CI): 1.27–4.15; P¼0.006). Among the 26
cases with intake of CCB, 20 had taken dihydropyridine,
whereas three and three had taken verapamil and diltiazem,
respectively. Among the 25 control patients with intake of
CCB, corresponding figures were 16, 8, and 1, respectively.
The OR of the association of verapamil with chronic
eczematous eruption was 2.72 (95% CI: 1.40–5.28;
P¼0.003). Interestingly, no significant associations were
found with any other drug classes (Table 2).
Drug classes that showed a separate association with
eczematous eruptions at the 0.15 level in univariate analysis,
namely antidepressants (P¼0.09), nitrates (P¼0.10),
and antiarrhythmics (P¼ 0.14) were retained in multi-
variate analysis. Upon adjusting for chronic intake of these
drugs, the association between CCB and eczematous
eruptions remained significant, with a slightly increased
OR of 2.45 (95% CI: 1.30–4.61; P¼0.0049). In this
analysis, chronic intakes of antidepressants, nitrates, and
antiarrhythmics showed again no significant associations
with eczematous eruptions (P¼0.31, 0.08, and 0.16,
respectively).
These analyses were repeated after excluding 19 cases
with elevated serum IgE levels (4500 IU/L) and their 38
matched controls. Indeed, although these patients had no
documented history of atopic dermatitis, their eczematous
eruption could potentially correspond to a late form of atopic
dermatitis in view of their high IgE levels. A significant
association of eczematous eruptions with CCB intake was
further evidenced, with about the same magnitude as on the
whole case–control sample (OR¼2.21; 95% CI: 1.15–4.24;
P¼0.02) in univariate analysis. Again, no association was
found with any other drugs and further adjusting for chronic
intake of antidepressants, nitrates, and antiarrhythmics, and
did not modify results appreciably (adjusted OR¼ 2.41; 95%
CI: 2.20–4.83; P¼0.01).
Table 1. Main characteristics of case and control patients
Case patients Control patients
Total
(n=102)
Inpatients
(n=49)
Outpatients
(n=53)
Total
(n=204)
Inpatients
(n=98)
Outpatients
(n=106) P-value*
Mean age7SD (years) 76.677.6 78.277.6 75.077.3 76.573.7 77.977.3 74.477.5 0.99**
Male/female sex ratio 1.83 1.23 2.79 1.83 1.23 2.79 1.00***
Mean number of drugs with chronic intake
(X3 months in reference year)7SD
4.773.3 5.673.6 4.172.7 4.573.2 4.973.0 4.173.3 0.56**
*Comparisons between all case patients and all control patients (irrespective of in/outpatient status).
**From Student’s t-test.
***From Pearson’s w2 test.
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When using a permutation-based (i.e., n¼13) correction
for multiple comparisons, the association between CCB and
eczematous eruptions was borderline significant (P¼0.058).
Finally, upon fitting an interaction term between in/outpatient
status and CCB intake, we obtained an OR for interaction of
1.01 (95% CI: 0.31–3.32), meaning that the association
between CCB intake and eczematous eruption was almost
identical in outpatients (OR¼2.28, 95% CI: 0.98–5.30) and
inpatients (OR¼2.31, 95% CI: 1.00–5.30).
Ancillary studies: Course of the eruptions after stopping CCBs
To ascertain the relationship between intake of CCB and
eczematous eruptions, we evaluated response to drug with-
drawal on two independent series of patients with chronic
eczematous eruptions. First, we retrospectively analyzed a
series of 74 patients older than 60 years who had been
referred to our department for chronic eczematous eruptions
without a known cause before the case–control study period
from January 1995 to January 2000. The main clinical
features of patients at baseline and main drugs used are
shown in Table 3. Some drugs were stopped in 54 patients,
whereas 20 patients did not have any drug withdrawal.
Among the 54 patients with drug withdrawal, CCBs were
stopped in 12 cases and other drugs in 42 cases. Long-lasting
(i.e., 46 months) recovery from the eruption was observed in
10 of the 12 patients (83%) who had stopped taking CCB after
a mean time of 3.471.8 months, as compared with 14 of 42
(33%) who had stopped other drugs, and four of the 20
patients (20%) who did not stop taking any drug (P¼0.001,
Fisher’s exact test). Interestingly, among the 42 patients who
had stopped taking various drugs other than CCB, eight
patients were taking CCB. Only one of them (12%) recovered
from his eruption while continuing to take CCB (P¼0.0045,
Fisher’s exact test for the comparison with the 12 patients
who had stopped CCB intake).
Second, we analyzed the main characteristics and follow-
up data of 101 patients having presented with eczematous
eruptions while being treated with CCB, who were registered
in the French National ‘‘Pharmacovigilance’’ database. The
keywords used were ‘‘eczema’’, ‘‘eczematous eruption’’, and
each of the CCB that are on the market in France. Their main
clinical features are displayed in Table 3. Twenty-two of them
(22%) had been hospitalized because of the severity of their
eruption. The median delay from their initial CCB intake to
the occurrence of their eczematous eruption was 91 days
(range: 30–3,600 days). Follow-up data were available for 67
cases. Thirty of the 53 patients (68%) who stopped taking
CCB recovered from their eczema, as compared with five of
the 14 (36%) who continued taking CCB (P¼0.03).
Rechallenge with CCB was performed in six cases from the
pharmacovigilance database and in three cases from authors.
Drugs involved were nicardipine (n¼ 6), amlodipine (n¼ 2),
and felodipine (n¼1). Drugs were taken for a mean time of
5.774.1 months before the onset of eruption. Mean delay to
resolution after drug withdrawal was 21.5713.1 days.
Rechallenge was performed after a mean time of 5.074.3
months after resolution of the eruption. It resulted in
the reoccurrence of the eruption in five of the six cases from
the pharmacovigilance database, and in the three cases
from the authors, after a mean time of 3.871.9 days.
Table 2. Univariate analysis of the association between chronic intake of drug classes and chronic or recurrent
eczematous eruptions
Case patients Control patients
Drug class
Total (n=102)
no (%) In-patients Outpatients
Total (n=204)
no (%) In-patients Outpatients
Odds ratio (95%
confidence
interval)* P-value*
Hypokalemic diuretics 29 (28) 15 (31) 14 (26) 67 (33) 39 (40) 28 (26) 0.80 (0.45–1.38) 0.39
Angiotensin-converting enzyme
inhibitors
29 (28) 15 (31) 14 (26) 58 (28) 33 (34) 25 (24) 1.00 (0.61–1.65) 1.00
Calcium channel blockers 26 (26) 14 (29) 12 (23) 25 (12) 14 (14) 11 (10) 2.29 (1.27–4.15) 0.006
Hypolipidemic drugs 25 (25) 14 (29) 11 (21) 38 (19) 15 (15) 23 (22) 1.39 (0.80–2.43) 0.25
Salicylates 23 (22) 11 (22) 12 (23) 40 (20) 26 (27) 14 (13) 1.22 (0.66–2.25) 0.53
Antiarrhythmics 20 (20) 8 (16) 12 (23) 27 (13) 13 (13) 14 (13) 1.64 (0.85–3.15) 0.14
Vasodilatators 19 (19) 9 (18) 10 (19) 40 (20) 20 (20) 20 (19) 0.94 (0.52–1.71) 0.84
b-Blockers 19 (19) 10 (20) 9 (17) 32 (16) 14 (14) 18 (17) 1.24 (0.65–2.35) 0.51
Nitrates 17 (17) 9 (18) 8 (15) 21 (10) 13 (13) 8 (8) 1.89 (0.89–3.99) 0.10
Benzodiazepines 16 (16) 10 (20) 6 (11) 32 (16) 16 (18) 16 (15) 1.00 (0.51–1.96) 1.00
Hyperkalemic diuretics 9 (9) 4 (8) 5 (9) 18 (9) 12 (12) 6 (6) 1.00 (0.44–2.26) 1.00
Antiulcers 9 (9) 5 (10) 4 (8) 18 (9) 8 (8) 10 (9) 1.00 (0.42–2.38) 1.00
Antidepressants 6 (6) 5 (10) 1 (2) 24 (12) 11 (11) 13 (12) 0.47 (0.80–1.19) 0.09
*From conditional logistic regression with no further adjustment considering all case and control patients (i.e., irrespective of in/outpatient status).
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DISCUSSION
This study showed an association between chronic intake of
CCB and chronic or recurrent eczematous eruptions of the
elderly with no known cause, whether patients with elevated
serum IgE levels, who could have a late yet undocumented
form of atopic dermatitis, were excluded or not. This
association appeared specific to CCB, as no associations
were found with any of the other 12 drug classes considered.
The role of CCB was difficult to suspect a priori in this context
where most patients had been taking many drugs often for a
long time (Be´gaud et al., 1985; Moore et al., 1985), a
situation that is rather similar to that of nicorandil-induced
giant aphthous ulcers, another drug-induced reaction that
mainly occurred in the elderly that we reported previously
(Agdo-Godeau et al., 1998).
The causative nature of this association is strongly
suggested by the high rate of recovery from these eruptions
after CCB withdrawal and the reappearance of eruptions after
rechallenge. A possible mechanism by which CCB might
induce eczematous dermatitis can be proposed. It has been
recently demonstrated that photodegraded nifedipine stimu-
lates uptake and retention of iron in human epidermal
keratinocytes (Gruen et al., 2001). Such a mechanism can
induce apoptosis and spongiosis of keratinocytes (Trautmann
et al., 2001), which may account for the histological picture
associating spongiosis and sparse keratinocyte necrosis seen
in skin biopsies from most patients with eczematous
eruptions who had taken CCB, as well as for the long delay
of recovery of these eruptions after drug withdrawal.
Chronic eczematous eruptions of the elderly seem
to correspond to an original skin disorder. Indeed, the
main characteristics of patients included in the case–control
study essentially confirmed the characteristics reported in
our preliminary study (6): (1) old age (mean age: 76 years);
(2) male predominance (sex ratio: 1.8); (3) substantial delay
from initial take of CCB to the occurrence of skin lesions
(3 months median delay); (4) occasional preferential localiza-
tion of skin lesions on sun-exposed areas (17%); and (5)
histological picture of eczema and sparse keratinocyte
necrosis. Similar characteristics were found in the two
ancillary studies. Despite a frequent good initial response
to topical corticosteroids, these eruptions can be severe
because of the intensity of pruritus, extent of cutaneous
lesions, and their relapsing course after topical corticosteroid
withdrawal. Indeed, 22% of patients registered in the
French National ‘‘Pharmacovigilance’’ database had been
hospitalized because of the severity of their eruption.
As in all case–control studies, various biases are possible in
this study. To avoid selection bias of cases, we aimed at
recruiting exhaustively all consecutive incident cases from
five regions in France, by relying both on office- and hospital-
based dermatologists. Indeed, recruiting only hospitalized
case patients could have led to the selection of more severe
forms, yielding bias in the event of a differential association of
drug exposure with eczema depending on disease severity.
The absence of major selection bias in our control patients is
supported by the similarities in the prevalence of the most
frequently used drugs in our control population as compared
with that observed in a series of 187 retired people in France
(Colomes et al., 1990) as well as with that observed in a
control series of 216 patients used in another case–control
study of elderly patients in France (Bastuji-Garin et al., 1996).
In particular, prevalences of cardiovascular drug intake in
these two series (64 and 54%, respectively) were rather
similar to that in our control series (48%), and the prevalence
of CCB intake (14% in both series) was very close to that in
our control series (12%).
Recall bias is a common problem in case–control studies,
especially those involving elderly subjects who may suffer
from memory impairment. However, because no specific
hypotheses had been raised before this study regarding
associations of chronic drug intake with chronic eczematous
eruptions of the elderly, differential recall bias is unlikely in
this study. Moreover, drug intake information provided by
case and control patients was systematically verified from
their pharmacist’s computerized database. Patients whose
eruptions had evolved for more than 18 months were not
included in this study to make this verification possible for all
patients. Indeed, the French pharmacists’ database only
covers the 18 months before the present time, information
before that period being erased on a continual basis. Finally,
the fact that the mean number of drugs was similar among
case and control patients supports the absence of major
Table 3. Main characteristics and drugs taken by
patients with chronic or recurrent eczematous
eruptions included in the two ancillary studies
evaluating patient outcome after drug withdrawal
Monocenter
study (n=74)
Study of patients in the
French
‘‘Pharmacovigilance’’
National Drug Survey
database (n=101)
Mean age7SD (years) 78.179.0 70.078.7
Male/female sex ratio 1.55 1.60
Past history of atopic
dermatitis no (%)
14 (19) 9 (9)
Preferential localization of
skin lesions on sun-
exposed areas no (%)
12 (16) 9 (9)
Mean number of drugs with
chronic intake
(X3 months)7SD
5.372.4 5.372.5
Main drug class no (%)
Converting enzyme
inhibitors
29 (39) 9 (9)
Calcium channel blockers 27 (36) 101 (100)
b-Blockers 22 (30) 6 (6)
Hypolipidemic drugs 22 (30) 5 (5)
Hypokalemic diuretics 17 (23) 9 (9)
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information bias in our study and supports the specificity of
the association with CCB.
Because we did not collect data on drugs used for a short
time, we cannot exclude the possibility that some drugs could
induce these eczematous reactions after short-term use.
However, this seems unlikely because most documented
drug-induced chronic skin disorders such as drug-induced
lupus erythematosus, pemphigus foliaceus, lichenoid reac-
tions, or psoriasis necessitate chronic drug exposure (Verdier-
Sevrain et al., 1994; Tsankov et al., 2000; Callen, 2001).
In conclusion, this study suggests that some chronic or
recurrent eczematous eruptions of the elderly may be due to
CCB. Although further studies would be necessary to confirm
this association and investigate further its causative nature, a
prudent attitude may be to discontinue CCB in elderly
patients with chronic eczema of unknown cause.
MATERIALS AND METHODS
This case–control study was conducted from 1 January 2000 to 31
December 2002 in five dermatology departments in University
Hospitals and in 35 private dermatology practices of five regions in
France.
Cases
Consecutive in- and outpatients older than 60 years at the onset
of cutaneous lesions were included. Inclusion criteria were
(1) eczematous eruptions corresponding to pruritic, erythematosus,
and vesicular lesions; (2) involving more than 20% of the body
surface; (3) having evolved continuously or recurrently (with more
than two recurrences) during a period from 3 to 18 months before
the study period; (4) without an identified cause, that is, excluding
patients with an history of atopic or contact dermatitis, eczema-like
mycosis fungoides, bullous pemphigoid, scabies, or nutritional
deficiency; (5) with histological features of eczema; and (6) a
negative direct immunofluorescence examination. All skin biopsies
were assessed by the same pathologist (PC). To detect a possible
atopic dermatitis in patients who had no history of atopic dermatitis,
serum total IgE level was determined in all patients, but patients
were not excluded on the basis of their IgE levels. Biological and
histological exams including blood cell count, albumin and total IgE
levels, and skin biopsy for standard histological and DIF examina-
tions were performed in all patients.
Controls
Two control patients were individually matched to each case based
on sex, age (within 5 years), origin (in- or outpatient), and center. For
cases recruited in private dermatology practices, matched controls
were selected from patients in the same practice presenting with any
dermatosis other than eczema or a documented drug-induced
reaction. These two controls were identified as the next two patients
fulfilling the matching criteria who were seen after the recruitment of
the case by the same dermatologists. For cases recruited in
dermatology departments, controls were selected from patients
referred the same day as the case to the emergency department of the
same hospital for an acute non-dermatological condition. The next
two patients fulfilling the matching criteria were identified from the
list of hospital admissions. If they agreed to participate in the study,
they were examined by investigators and used as controls if they did
not have a current or past history of eczema. The proportions of
in- and outpatient cases and controls were not significantly different
among centers.
Assessment of drug intake
Based on the findings from our preliminary study (Morin et al.,
2002), we postulated that an association between chronic eczema-
tous eruptions and drug intake, if any, would require several months
of treatment. Therefore, we collected data on drugs used for at least 3
months within the year preceding the onset of the first eczematous
eruption in cases, and during the same calendar period in controls.
Drug information was obtained first by asking patients to name the
drugs they had taken for the past year. Then, they were required to
present any available written prescription from their physician.
Confirmation was sought systematically by asking each patient’s
usual pharmacist to verify the patient’s drug use from their
computerized database. In case of discordance, the information
provided by the pharmacist was retained. According to the French
law, this type of study in which patients are only asked about their
drug intake without any intervention does not require the approval of
an Ethics Committee.
Statistical analysis
The target sample size was 106 cases and 212 controls (2:1
matching). It was calculated to detect a matched OR of 2.5 for drugs
with a prevalence of chronic intake (i.e., Xthree months) of 10%
among controls, with 80% power, and for a two-sided type I error of
5%.
Only the drug classes used with a prevalence of chronic intake
over 5% among the controls were considered. In univariate analysis,
matched OR with their 95% CI were estimated using conditional
logistic regression. All drugs presenting an association with chronic
or recurrent eczema with P p0.15 was retained for the subsequent
multivariate analysis that used conditional logistic regression to
assess independent associations with eczematous eruptions.
All analyses were repeated for matched sets, in which there was
no elevation of IgE levels (o500 IU) in the case. Statistical analyses
were performed using version 2.0.31 of Egret software and version
3.1 of StatXact-3 software (both from Cytel Software Corporation,
Cambridge, MA).
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